Novartis’ results show the firm humming along nicely in 2024, with sales driven by continued strong performance from its ...

Q4 2024 Earnings Call Transcript January 31, 2025 Novartis AG beats earnings expectations. Reported EPS is $1.98, ...

Good morning and good afternoon, and welcome to the Novartis Q4 2024 results release conference call and live webcast.

Novartis says it has 5 oncology drugs and 2 cardiovascular, renal, and metabolic drugs at the registrational stage, i.e., pending commercial approval, as shown below: While the oncology approvals ...

Novartis on Friday posted adjusted net income well above analyst estimates as sales of established heart failure drug ...

Novartis reported strong Q4 earnings and sales growth, with CEO Narasimhan reportedly downplaying concerns over Entresto's ...

Unlike other brands that release their ads days or weeks ahead of the Big Game, Novartis is waiting to unveil its commercial ...

Novartis shares jumped 3.6% to a three-month high of 97.15 francs at 0941 GMT, with investors also encouraged by the company's upbeat 2025 earnings projections. Entresto, which will lose patent ...